Immune dysfunction in dialysis patients--prevention and treatment strategies.
Immune dysfunction, resulting in infection or inflammation, or both, is closely associated with poor clinical outcome in end-stage renal disease patients. So far, no single measure can effectively address this condition, because many factors, such as uremia per se and dialysis treatment are involved in the pathogenesis. Our review focuses on currently available treatments and prevention options, and identifies future research needs.
Tranaeus
Anders
A
Baxter Renal Division, Asia Pacific, Shanghai, PR China. tranaea@baxter.com
Yao
Qiang
Q
D050154:Adiposity / Q000276:immunology; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D015314:Dialysis Solutions / Q000378:metabolism; D017583:Hemodiafiltration / Q000009:adverse effects*; D006801:Humans; D007154:Immune System Diseases / Q000209:etiology* / Q000517:prevention & control*; D007239:Infections / Q000150:complications / Q000628:therapy; D007676:Kidney Failure, Chronic / Q000150:complications; D010530:Peritoneal Dialysis / Q000009:adverse effects*; D014511:Uremia / Q000150:complications; D014882:Water-Electrolyte Balance
D000893:Anti-Inflammatory Agents; D015314:Dialysis Solutions